Cell Death Dis:鼠尾草酚可抑制炎性小体活化,或可用于治疗相关疾病

2020-04-25 QQY MedSci原创

鼠尾草酚可抑制炎性小体的活化,或可作为治疗炎性小体介导的炎症相关疾病的安全有效的候选药物。

炎性小体是一种多蛋白复合物,可以被病原相关分子模式(PAMP)及危险相关分子模式(DAMP)激活,进而激活caspase-1,最后导致细胞凋亡反应和IL-1β(白介素1β)及IL-181-3的产生。

既往研究发现,炎症小体能够参与各种代谢类疾病及炎症相关疾病。在模拟各种人类疾病的动物模型中,炎症小体的药理抑制剂均产生显著的治疗效果。因此,炎症小体被广泛认为是治疗多种疾病的新靶标。

在该研究中,研究人员发现鼠尾草酚(carnosol)可以通过直接靶向HSP90(热休克蛋白90)来抑制NLRP3炎性小体的活化,进而对炎性小体介导的相关疾病起到治疗作用。

研究数据表明,鼠尾草酚能够抑制原代小鼠BMDM细胞(骨髓源性巨噬细胞)、THP-1细胞及hPBMC(人外周血单核细胞)中的NLRP3炎性小体的活化。

机制研究发现,鼠尾草酚通过与HSP90结合抑制其ATPase酶活性并抑制炎性小体的活化过程。体内实验结果表明,在NLRP3炎性小体介导的疾病(包括内毒素血症及非酒精性脂肪性肝炎[NASH])小鼠模型中鼠尾草酚具有显著的治疗作用。

此外,研究人员还发现对小鼠进行持续两周的鼠尾草酚(120 mg/kg,1/日,腹腔注射)治疗,给药小鼠表现出良好的耐受性。

综上,研究结果揭示了鼠尾草酚可抑制炎性小体的活化,或可作为治疗炎性小体介导的炎症相关疾病的安全有效的候选药物。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1871703, encodeId=926e18e1703b6, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Jan 10 05:49:39 CST 2021, time=2021-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2082260, encodeId=4f8d20822601b, content=<a href='/topic/show?id=b66410338390' target=_blank style='color:#2F92EE;'>#鼠尾草酚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103383, encryptionId=b66410338390, topicName=鼠尾草酚)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIW7uIr5ebYvJohUq0dkkVV05uF9jPpeyCrlcx904mUdMI9UKqpO3bt4GkgYBNdv485qT2NsVE27w/132, createdBy=023c2500122, createdName=ms8543593053280928, createdTime=Fri Aug 07 07:49:39 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961997, encodeId=f523196199e96, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sun Jul 12 00:49:39 CST 2020, time=2020-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1957818, encodeId=a32b195e81813, content=<a href='/topic/show?id=0c7b669e992' target=_blank style='color:#2F92EE;'>#炎性小体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66979, encryptionId=0c7b669e992, topicName=炎性小体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Wed Nov 25 01:49:39 CST 2020, time=2020-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013324, encodeId=f920201332420, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sat Apr 10 03:49:39 CST 2021, time=2021-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531603, encodeId=f9e615316037e, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Mon Apr 27 08:49:39 CST 2020, time=2020-04-27, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1871703, encodeId=926e18e1703b6, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Jan 10 05:49:39 CST 2021, time=2021-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2082260, encodeId=4f8d20822601b, content=<a href='/topic/show?id=b66410338390' target=_blank style='color:#2F92EE;'>#鼠尾草酚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103383, encryptionId=b66410338390, topicName=鼠尾草酚)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIW7uIr5ebYvJohUq0dkkVV05uF9jPpeyCrlcx904mUdMI9UKqpO3bt4GkgYBNdv485qT2NsVE27w/132, createdBy=023c2500122, createdName=ms8543593053280928, createdTime=Fri Aug 07 07:49:39 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961997, encodeId=f523196199e96, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sun Jul 12 00:49:39 CST 2020, time=2020-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1957818, encodeId=a32b195e81813, content=<a href='/topic/show?id=0c7b669e992' target=_blank style='color:#2F92EE;'>#炎性小体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66979, encryptionId=0c7b669e992, topicName=炎性小体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Wed Nov 25 01:49:39 CST 2020, time=2020-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013324, encodeId=f920201332420, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sat Apr 10 03:49:39 CST 2021, time=2021-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531603, encodeId=f9e615316037e, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Mon Apr 27 08:49:39 CST 2020, time=2020-04-27, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1871703, encodeId=926e18e1703b6, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Jan 10 05:49:39 CST 2021, time=2021-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2082260, encodeId=4f8d20822601b, content=<a href='/topic/show?id=b66410338390' target=_blank style='color:#2F92EE;'>#鼠尾草酚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103383, encryptionId=b66410338390, topicName=鼠尾草酚)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIW7uIr5ebYvJohUq0dkkVV05uF9jPpeyCrlcx904mUdMI9UKqpO3bt4GkgYBNdv485qT2NsVE27w/132, createdBy=023c2500122, createdName=ms8543593053280928, createdTime=Fri Aug 07 07:49:39 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961997, encodeId=f523196199e96, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sun Jul 12 00:49:39 CST 2020, time=2020-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1957818, encodeId=a32b195e81813, content=<a href='/topic/show?id=0c7b669e992' target=_blank style='color:#2F92EE;'>#炎性小体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66979, encryptionId=0c7b669e992, topicName=炎性小体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Wed Nov 25 01:49:39 CST 2020, time=2020-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013324, encodeId=f920201332420, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sat Apr 10 03:49:39 CST 2021, time=2021-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531603, encodeId=f9e615316037e, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Mon Apr 27 08:49:39 CST 2020, time=2020-04-27, status=1, ipAttribution=)]
    2020-07-12 docwu2019
  4. [GetPortalCommentsPageByObjectIdResponse(id=1871703, encodeId=926e18e1703b6, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Jan 10 05:49:39 CST 2021, time=2021-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2082260, encodeId=4f8d20822601b, content=<a href='/topic/show?id=b66410338390' target=_blank style='color:#2F92EE;'>#鼠尾草酚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103383, encryptionId=b66410338390, topicName=鼠尾草酚)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIW7uIr5ebYvJohUq0dkkVV05uF9jPpeyCrlcx904mUdMI9UKqpO3bt4GkgYBNdv485qT2NsVE27w/132, createdBy=023c2500122, createdName=ms8543593053280928, createdTime=Fri Aug 07 07:49:39 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961997, encodeId=f523196199e96, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sun Jul 12 00:49:39 CST 2020, time=2020-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1957818, encodeId=a32b195e81813, content=<a href='/topic/show?id=0c7b669e992' target=_blank style='color:#2F92EE;'>#炎性小体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66979, encryptionId=0c7b669e992, topicName=炎性小体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Wed Nov 25 01:49:39 CST 2020, time=2020-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013324, encodeId=f920201332420, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sat Apr 10 03:49:39 CST 2021, time=2021-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531603, encodeId=f9e615316037e, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Mon Apr 27 08:49:39 CST 2020, time=2020-04-27, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1871703, encodeId=926e18e1703b6, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Jan 10 05:49:39 CST 2021, time=2021-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2082260, encodeId=4f8d20822601b, content=<a href='/topic/show?id=b66410338390' target=_blank style='color:#2F92EE;'>#鼠尾草酚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103383, encryptionId=b66410338390, topicName=鼠尾草酚)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIW7uIr5ebYvJohUq0dkkVV05uF9jPpeyCrlcx904mUdMI9UKqpO3bt4GkgYBNdv485qT2NsVE27w/132, createdBy=023c2500122, createdName=ms8543593053280928, createdTime=Fri Aug 07 07:49:39 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961997, encodeId=f523196199e96, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sun Jul 12 00:49:39 CST 2020, time=2020-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1957818, encodeId=a32b195e81813, content=<a href='/topic/show?id=0c7b669e992' target=_blank style='color:#2F92EE;'>#炎性小体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66979, encryptionId=0c7b669e992, topicName=炎性小体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Wed Nov 25 01:49:39 CST 2020, time=2020-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013324, encodeId=f920201332420, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sat Apr 10 03:49:39 CST 2021, time=2021-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531603, encodeId=f9e615316037e, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Mon Apr 27 08:49:39 CST 2020, time=2020-04-27, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1871703, encodeId=926e18e1703b6, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Jan 10 05:49:39 CST 2021, time=2021-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2082260, encodeId=4f8d20822601b, content=<a href='/topic/show?id=b66410338390' target=_blank style='color:#2F92EE;'>#鼠尾草酚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103383, encryptionId=b66410338390, topicName=鼠尾草酚)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIW7uIr5ebYvJohUq0dkkVV05uF9jPpeyCrlcx904mUdMI9UKqpO3bt4GkgYBNdv485qT2NsVE27w/132, createdBy=023c2500122, createdName=ms8543593053280928, createdTime=Fri Aug 07 07:49:39 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961997, encodeId=f523196199e96, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sun Jul 12 00:49:39 CST 2020, time=2020-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1957818, encodeId=a32b195e81813, content=<a href='/topic/show?id=0c7b669e992' target=_blank style='color:#2F92EE;'>#炎性小体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66979, encryptionId=0c7b669e992, topicName=炎性小体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Wed Nov 25 01:49:39 CST 2020, time=2020-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013324, encodeId=f920201332420, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sat Apr 10 03:49:39 CST 2021, time=2021-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531603, encodeId=f9e615316037e, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Mon Apr 27 08:49:39 CST 2020, time=2020-04-27, status=1, ipAttribution=)]
    2020-04-27 cy0328

相关资讯

Sci Rep:在热激蛋白90调控抑制的膀胱癌疗法中,蛋白组和组蛋白翻译后修饰的蛋白组学分析

热激蛋白90(HSP90)的抑制作用的利用是一个非常诱人用于癌症治疗的策略。一些HSP90抑制剂在临床肿瘤试验中展现了很有应用前途的效果。然而,关于HSP90调控抑制的膀胱癌疗法的机制所知甚少。最近,研究人员报道了一个数量蛋白组学研究,即当蛋白表达量的改变和组蛋白翻译后修饰(PTMs)改变时,膀胱癌对HSP90抑制作用响应的评估。研究展示了5种HSP90抑制剂(AUY922, ganetespib

CLIN CANCER RES:BRAF和HSP90抑制剂联合治疗不可切除的黑色素瘤

BRAF抑制剂对晚期BRAF V600突变黑色素瘤患者具有临床活性,但获得性耐药仍然很常见。临床前研究表明,使用HSP90抑制剂XL888联合治疗可以克服耐药性。CLIN CANCER RES近期发表了一篇文章,报道了两种药物联合的临床试验结果

Sci Rep:开发新型Hsp90抑制剂NCT-50作为非小细胞肺癌的潜在抗癌药

这些结果表明了NCT-50作为抗癌Hsp90抑制剂的潜力。

Free Radic Biol Med:褪黑素能够保护人类冷冻精液中精子的活力!

随着各种辅助生殖技术的发展,冷冻精液的应用越来越多,而精子在精液冷冻保存过程中可能会发生物理损伤和氧化应激导致繁殖能力的降低。抗氧化剂如天然抗氧化褪黑素可能可以改善冷冻保存结果。

Cancer Res:科学家发现热激蛋白抑制剂 或可用于癌症治疗

有研究发现热激蛋白Hsp90能够帮助参与癌症进展的信号蛋白进行正确折叠,因此成为癌症治疗干预的一个新靶点得到科学家们关注。天然鱼藤酮类化合物鱼藤素是Hsp90的一种抑制剂,但该化合物的神经毒性大大限制了其作为抗癌药物在临床领域的应用前景。   近日,来自首尔大学的研究人员在国际学术期刊cancer research上发表了一项最新研究进展,在这项研究中他们找到一种鱼藤素类似物解决

联合靶向BRAF和HSP90的药物显示了黑素瘤治疗潜能

科学家们尝试将药物联合起来,以预防导致黑色素瘤患者癌症再生的抗性的发展。由于过去十年已批准的几种新疗法,如BRAF和MEK抑制剂,晚期或转移性黑素瘤患者能够延长无疾病进展生存期。然而,尽管这些靶向药物取得了部分成功,但大多数患者最终会产生耐药性,导致癌症再生。